Posts by WGNV

Tuberculosis and T cells: Impact of T cell diversity in tuberculosis infection. Vats D, Rani G, Arora A, Sharma V, Rathore I, Mubeen SA, Singh A. Tuberculosis (Edinb). 2024 Dec;149:102567. doi: 10.1016/j.tube.2024.102567. Epub 2024 Sep 18.   A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis. Hu Z, Xia…

Bioinformatics Analysis and Immunogenicity Assessment of the Novel Multi-Stage DNA Vaccine W541 Against Mycobacterium Tuberculosis. Yang Y, Xue Y, Wang X, Wang L, Wang J, Zhang J, Liu Y, Liang Y, Wu X. Immun Inflamm Dis. 2024 Nov;12(11):e70074. doi: 10.1002/iid3.70074.  Multilevel Proteomics Reveals Epigenetic Signatures in BCG-Mediated Macrophage Activation. Schaefer Z, Iradukunda J, Lumngwena EN,…

Implications of subclinical tuberculosis for vaccine trial design and global effect Churchyard GJ, Houben RMGJ, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG. Lancet Microbe. 2024 Oct;5(10):100895. doi: 10.1016/S2666-5247(24)00127-7. Epub 2024 Jul 1. …

Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development. Karunakaran KP, Yu H, Jiang X, Chan QWT, Sigola L, Millis LA, Chen J, Tang P, Foster LJ, Brunham RC. Vaccine. 2024 Sep 2;42(24):126266. doi: 10.1016/j.vaccine.2024.126266. Epub ahead of print.   Antibodies as key mediators…

Implications of subclinical tuberculosis for vaccine trial design and global effect. Churchyard GJ, Houben RMGJ, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG. Lancet Microbe. 2024 Jul 1. doi: 10.1016/S2666-5247(24)00127-7. Epub ahead of…